Neptune's Board of Directors Welcomes Dr. Harlan Waksal
2012年5月23日 - 9:00PM
Neptune Technologies & Bioressources Inc. ("Neptune" or the
"Corporation") (Nasdaq:NEPT) (TSX:NTB) is pleased to announce that
Dr. Harlan Waksal, Executive Vice-President, Business &
Scientific Operations of Acasti Pharma Inc. was appointed to the
Corporation's Board of Directors.
"Harlan has extraordinary scientific and business expertise, and
we are delighted that he is joining Neptune's board of directors,"
said Dr. Ronald Denis, Neptune's Chairman.
Dr. Harlan Waksal is a retired physician, founder of Imclone
System Inc. in which he has been involved as the President, Chief
Executive Officer, Chief Operating Officer and Executive
Vice-President from 1987 to 2003. Imclone System has developed and
obtained approval for a new targeted biologic cancer therapy known
as Erbitux and was later acquired by Eli Lily for $6.5 B US in
October 2008. Dr. Harlan Waksal currently seats on the Board of
Directors of Oberlin College and Senesco Technologies, is the
author of over 50 scientific publications and has been the author
of multiple patents and patents applications. Furthermore, Dr.
Waksal is currently the Executive Vice-President, Business &
Scientific Operations of Acasti Pharma Inc, Neptune's
subsidiary.
"I am thrilled to join the Neptune board and work with this
exceptional team," Waksal said. "Neptune has been a leader and
pioneer with Neptune Krill oil of this new and promising generation
of Omega-3, and I look forward to sharing my experiences and
contributing to the future direction and growth of this exciting
company."
"Dr. Harlan Waksal brings unique insight and experience to fuel
our next phases of growth," stated Henri Harland, CEO. "This new
addition to our board strongly positions the company to execute on
our mission to develop and prosper in the Phospholipids Omega-3
market and in the meantime enhance shareholder's value.''
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 30
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX) accepts responsibility for the adequacy or accuracy of this
release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024